Anaphylaxis to chemotherapy and monoclonal antibodies

Immunology and Allergy Clinics of North America

Volumn 35, Issue 2, 2015, Pages 335-348

  Castells, Mariana C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anaphylaxis; Chemotherapy; Monoclonal antibodies; Platins; Rapid desensitization; Skin testing; Taxenes; Tryptase

Indexed keywords

ABCIXIMAB; ADRENALIN; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CABAZITAXEL; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETANERCEPT; ETOPOSIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OMALIZUMAB; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; RITUXIMAB; STEROID; TAXANE DERIVATIVE; TENIPOSIDE; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; IMMUNOGLOBULIN E; TRYPTASE;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ANAPHYLAXIS; ARTHRALGIA; ASTHMA; BACKACHE; BREAST CANCER; BRONCHOSPASM; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CHILL; CLINICAL FEATURE; CROSS REACTION; CYTOKINE RELEASE SYNDROME; DESENSITIZATION; DIAGNOSTIC VALUE; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; INTRACUTANEOUS TEST; LARYNX EDEMA; LUNG CANCER; LYMPHOMA; MALAISE; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEOPLASM; NEUTROPENIA; OVARY CANCER; OXYGEN DESATURATION; PRESYNCOPE; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; RISK ASSESSMENT; SERUM SICKNESS; SIDE EFFECT; SKIN DISEASE; SKIN TEST; SMALL CELL LUNG CANCER; SOLID TUMOR; TESTIS TUMOR; THORAX PAIN; THROAT TIGHTNESS; URTICARIA; VOMITING; DRUG HYPERSENSITIVITY; IMMUNOLOGY;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; SKIN TESTS; TRYPTASES;

EID: 84926389754     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.01.011     Document Type: Review

References (60)

1. Weiss R.B. Hypersensitivity reactions. Semin Oncol 1992, 19:458-477.
2. Sakaeda T., Kadoyama K., Yabuuchi H., et al. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011, 8:332-338.
3. Kadoyama K., Kuwahara A., Yamamori M., et al. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. JExp Clin Cancer Res 2011, 30:93.
4. Schwartz L.B. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin N Am 2006, 26:451-463.
5. Hesterberg P.E., Banerji A., Oren E., et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. JAllergy Clin Immunol 2009, 123:1262-1267.e1.
6. Patil S.U., Long A.A., Ling M., et al. Aprotocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. JAllergy Clin Immunol 2012, 129:443-447.
7. Lee C.W., Matulonis U.A., Castells M.C. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004, 95:370-376.
8. Brennan P.J., Rodriguez Bouza T., Hsu F.I., et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. JAllergy Clin Immunol 2009, 124:1259-1266.
9. Prieto Garcia A., Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. JInvestig Allergol Clin Immunol 2010, 20:170-171.
10. Castells M.C., Tennant N.M., Sloane D.E., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. JAllergy Clin Immunol 2008, 122(3):574-580.
11. del Carmen Sancho M., Breslow R., Sloane D., et al. Desensitization for hypersensitivity reactions to medications. Chem Immunol Allergy 2012, 97:217-233.
12. McNeil B.D., Pundir P., Meeker S., et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2014, [Epub ahead of print].
13. Hsu Blatman K.S., Castells M.C. Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes. Curr Allergy Asthma Rep 2014, 14:453.
14. Wong J.T., Ling M., Patil S., et al. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. JAllergy Clin Immunol Pract 2014, 2:40-45.
15. Mezzano V., Giavina-Bianchi P., Picard M., et al. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs 2014, 28:133-144.
16. Moon D.H., Lee J.M., Noonan A.M., et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 2013, 109:1072-1078.
17. Cristaudo A., Sera F., Severino V., et al. Occupational hypersensitivity to metal salts, including platinum, in the secondary industry. Allergy 2005, 60:159-164.
18. Markman M., Kennedy A., Webster K., et al. Clinical features of hypersensitivity reactions to carboplatin. JClin Oncol 1999, 17:1141.
19. Navo M., Kunthur A., Badell M.L., et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006, 103:608-613.
20. Lazzareschi I., Ruggiero A., Riccardi R., et al. Hypersensitivity reactions to carboplatin in children. JNeurooncol 2002, 58:33-37.
21. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006, 6:476-481.
22. Banerji A., Lax T., Guyer A., et al. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. JAllergy Clin Immunol Pract 2014, 2:428-433.
23. Feldweg A.M., Lee C.W., Matulonis U.A., et al. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005, 96:824-829.
24. Decorti G., Bartoli Klugmann F., Candussio L., et al. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 1996, 16:317-320.
25. Afatal anaphylactic reaction to paclitaxel is described, which was preceded by apossible delayed reaction to the initial infusion. Allergy Asthma Proc 2011, 32:79.
26. Denman J.P., Gilbar P.J., Abdi E.A. Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. JClin Oncol 2002, 20:2760-2761.
27. Fader A.N., Rose P.G. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 2009, 19:1281-1283.
28. Huddleston R., Berkheimer C., Landis S., et al. Improving patient outcomes in an ambulatory infusion setting: decreasing infusion reactions of patients receiving paclitaxel and carboplatin. JInfus Nurs 2005, 28:170-172.
29. Weiss R.B., Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981, 94:66-72.
30. Stone H.D., DiPiro C., Davis P.C., et al. Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolated-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. JAllergy Clin Immunol 1998, 101:429-431.
31. Soyer O.U., Aytac S., Tuncer A., et al. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. JAllergy Clin Immunol 2009, 123:895-899.
32. Guo Y. Desensitization therapy of acute lymphocytic leukemia with injection of L-asparaginase (Report of 5 cases). Zhonghua Er Ke Za Zhi 2005, 43:309-310. [in Chinese].
33. O'Dwyer P.J., Weiss R.B. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 1984, 68:959-961.
34. Hong D.I., Bankova L., Cahill K.N., et al. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol 2012, 8:43-52. [quiz: 53-4].
35. Vultaggio A., Castells M.C. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin N Am 2014, 34:615-632. ix.
36. Cheifetz A., Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005, 72:250-256.
37. Cernadas J.R., Brockow K., Romano A., et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010, 65:1357-1366.
38. Kang S.P., Saif M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-Identification, prevention, and management. JSupport Oncol 2007, 5:451-457.
39. Vultaggio A., Matucci A., Nencini F., et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657-661.
40. Bavbek S., Ataman S., Bankova L., et al. Injection site reaction to adalimumab: positive skin test and successful rapid desensitisation. Allergol Immunopathol (Madr) 2013, 41:204-206.
41. Dereure O., Navarro R., Rossi J.F., et al. Rituximab-induced vasculitis. Dermatology 2001, 203:83-84.
42. D'Arcy C.A., Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001, 44:1717-1718.
43. Gamarra R.M., McGraw S.D., Drelichman V.S., et al. Serum sickness-like reactions in patients receiving intravenous infliximab. JEmerg Med 2006, 30:41-44.
44. Pilette C., Coppens N., Houssiau F.A., et al. Severe serum sickness-like syndrome after omalizumab therapy for asthma. JAllergy Clin Immunol 2007, 120:972-973.
45. Stallmach A., Giese T., Schmidt C., et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004, 16:627-630.
46. Castells M., Pichler W.J. Drug desensitization in oncology: chemotherapy agents and monoclonal antibodies. Drug hypersensitivity 2007, 413-425. Karger, New York. W. Pichler (Ed.).
47. Chung C.H., Mirakhur B., Chan E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. NEngl J Med 2008, 358:1109-1117.
48. Wolbink G.J., Vis M., Lems W., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
49. Finkelman F.D. Anaphylaxis: lessons from mouse models. JAllergy Clin Immunol 2007, 120:506-515.
50. Vultaggio A., Matucci A., Nencini F., et al. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Intern Emerg Med 2012, 7(Suppl 2):S77-S79.
51. Jacobstein D.A., Markowitz J.E., Kirschner B.S., et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005, 11:442-446.
52. Commins S.P., Platts-Mills T.A. Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. JAllergy Clin Immunol 2009, 124:652-657.
53. Markman M., Zanotti K., Peterson G., et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. JClin Oncol 2003, 21:4611-4614.
54. Callahan M.B., Lachance J.A., Stone R.L., et al. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 2007, 197:199.e1-199.e4. [discussion: 199.e4-5].
55. Caiado J., Venemalm L., Pereira-Santos M.C., et al. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. JAllergy Clin Immunol Pract 2013, 1:494-500.
56. Madrigal-Burgaleta R., Berges-Gimeno M.P., Angel-Pereira D., et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013, 68:853-861.
57. Iwamoto T., Yuta A., Tabata T., et al. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull 2012, 35:1487-1495.
58. Morales A.R., Shah N., Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005, 94:575-580.
59. Zhao W., Gomez G., Macey M., et al. Invitro desensitization of human skin mast cells. JClin Immunol 2012, 32:150-160.
60. Oka T., Rios E.J., Tsai M., et al. Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells. JAllergy Clin Immunol 2013, 132:922-932.e1-16.